Kinase Inhibitors: Global Markets

Published - Jun 2012| Analyst - Shalini Shahani Dewan| Code - BIO053C
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

The global kinase inhibitors market reached $28.1 billion in 2010 and nearly $29.1 billion in 2011. The market is expected to reach $40.2 billion by 2016, a compound annual growth rate (CAGR) of 6.7%.

Report Scope

The scope of this study encompasses kinase inhibitors in pharmaceutical and biotechnology markets.  BCC analyzes each market and its applications, regulatory environment, technology, market projections and market share.  Technological issues include the latest trends and developments.  The emerging market for enzyme inhibitors includes India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand and others countries.

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Latest reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Nov-2009| Analyst - Brian Lawler| Code - BIO053B

Report Highlights

  • Overall sales in the global market for kinase inhibitors were nearly $14 billion in 2008 which increased to $15.2 billion in 2009. By 2014, it is estimated to increase to $20.2 billion, at 5 year compound annual growth rate (CAGR) of 5.8%.
  • The largest segment receptor tyrosine kinase inhibitors market was nearly $9.4 billion in 2008; which increased to $10 billion in 2009. This is expected to rise to $13.1 billion in 2014, a CAGR of 5.5%.
  • Sales in serine/threonine kinase inhibitors (STKIs) reached approximately $512 million in 2008. This further increased to $855 million in 2009 and is projected to reach $1.4 billion in 2014, at a CAGR of 10.7%.
Published - Jan-2006| Analyst - Amy Brock| Code - BIO053A

Report Highlights

  • The worldwide market for kinase inhibitors for clinical use will reach $4.63 billion in 2005 and will rise at an average annual growth rate (AAGR) of 20.6% to $11.8 billion by 2010.
  • Receptor tyrosine kinase inhibitors comprise 49.8% of the total market in 2005 and are projected to grow at an AAGR of 26.6% to account for 63.7% of the total in 2010.
  • Nonreceptor tyrosine kinase inhibitors, consisting of BCR-Abl kinase inhibitor, reached sales of $1.86 billion in 2005. They are projected to increase at an AAGR of 13.7% to reach $3.56 billion in 2010.
  • The major disease application for kinase inhibitors is oncology that comprised nearly 90% of kinase inhibitor sales in 2005 and is expected to grow at an AAGR of 21.5%.

CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report